Benign recurrent intrahepatic cholestasis
Overview
Benign recurrent intrahepatic cholestasis (BRIC) is a rare, inherited liver disorder characterized by repeated, temporary episodes of cholestasis—a condition where the flow of bile from the liver is reduced or blocked.
Despite severe symptoms during an attack, the disease is "benign" because it does not cause permanent, progressive liver damage or cirrhosis.
Symptoms
An episode typically starts in adolescence or young adulthood (teens or twenties) and includes the following signs:
• Severe Itchiness (Pruritus): This is usually the very first symptom to appear, often becoming intense and debilitating before other signs show up.
• Jaundice: A few weeks after the itching starts, the skin and the whites of the eyes turn yellow.
• Dark Urine and Pale Stools: Urine may become dark or tea-colored, while bowel movements can turn pale, clay-colored, or acholic due to a lack of bile entering the gut.
• Digestive and GI Issues: Nausea, vomiting, a vague feeling of upper abdominal discomfort, and a total loss of appetite (anorexia).
• Fat Malabsorption (Steatorrhea): Because the body struggles to process and absorb fats properly, stools can become bulky, greasy, or excessively fatty.
• Fatigue and Malaise: General tiredness, a heavy feeling of weakness, and irritability are common during a flare-up.
• Weight Loss: Caused by poor fat absorption and a lack of appetite during active episodes.
• Hepatomegaly: Enlargement of the liver can sometimes be detected during an examination.
• BRIC Type 1: May sometimes include extrahepatic (outside the liver) symptoms such as chronic diarrhea, pancreatitis (inflammation of the pancreas), or hearing impairment.
• BRIC Type 2: Is more frequently associated with the development of gallstones (cholelithiasis).
Causes
BRIC is classified into two main subtypes based on the specific gene affected:
• BRIC Type 1: Caused by mutations in the ATP8B1 gene, which leads to dysfunction in an ATP-dependent ion pump necessary for maintaining normal cell membrane stability in the liver.
• BRIC Type 2: Caused by mutations in the ABCB11 gene, which impairs the function of the BSEP (bile salt export pump) protein responsible for moving bile salts out of liver cells.
• Infections: Viral infections are the most frequently reported trigger.
• Hormonal Changes: Pregnancy, the use of oral contraceptive pills, or other natural hormonal fluctuations.
• Medications: Certain drugs that impact liver or bile processing.
• Stress or Emotional/Physical Fatigue: General systemic stress on the body.
Diagnosis
A clinical diagnosis of BRIC is traditionally established when a patient meets these core features:
• Recurrent Episodes: At least two distinct episodes of jaundice separated by symptom-free intervals lasting months to several years.
• Severe Itching (Pruritus): Intense, debilitating pruritus that typically precedes the onset of jaundice.
• Cholestatic Laboratory Profile: Elevated conjugated (direct) bilirubin and serum bile acids, combined with normal or low-normal gamma-glutamyl transferase (GGT) levels—a critical hallmark that distinguishes BRIC from many other liver and bile duct disorders.
• Normal Biliary Imaging: Cholangiography (such as MRCP or endoscopic ultrasound) showing normal intra- and extrahepatic bile ducts with no mechanical obstruction or gallstones (though BRIC2 is sometimes associated with gallstones).
• Histology: Liver biopsy showing bland centrilobular/canalicular cholestasis with preserved architecture and the absence of significant inflammation, fibrosis, or cirrhosis.
• Exclusion of Alternatives: Rulings out other causes of chronic or recurrent cholestasis, including drug-induced liver injury, viral hepatitis, autoimmune liver diseases, and extrahepatic blockages
Definitive molecular confirmation is achieved via next-generation sequencing or targeted gene panels identifying pathogenic variants in PMC11235557:
• BRIC Type 1: Mutations in the ATP8B1 gene.
• BRIC Type 2: Mutations in the ABCB11 gene (encoding the bile salt export pump, or BSEP).
Treatment
• Rifampicin: Often used to shorten the duration of cholestatic episodes and reduce severe itching (pruritus) by stimulating bile acid metabolism and clearance.
• Bile Acid Sequestrants: Cholestyramine binds bile acids in the intestine so they are excreted in stool, helping ease pruritus.
• Ursodeoxycholic Acid (UDCA): Frequently prescribed to help improve bile flow and liver biochemistry, though response varies by patient.
• Other Itching Medications: Antihistamines, centrally acting opioid antagonists (like naltrexone), or serotonin reuptake inhibitors are sometimes added for resistant pruritus.
• Endoscopic Nasobiliary Drainage (ENBD): A temporary nasal tube that drains bile directly from the bile ducts to rapidly relieve severe itching and jaundice.
• Extracorporeal Albumin Dialysis (MARS): A specialized dialysis system (Molecular Adsorbents Recirculation System) that filters albumin-bound toxins, bilirubin, and bile acids out of the blood.
• Plasmapheresis: Exchanging blood plasma to remove circulating pruritogens (itch-inducing substances) during severe attacks.
• Surgical Biliary Diversion: Partial external biliary diversion is occasionally performed in severe, frequent cases to lower the bile acid load on the body
Liver Transplantation: Very rarely considered and generally avoided unless episodes are completely intractable and severely degrade quality of life, or if overlapping progressive disease features are present.of
Type of Doctor Department : A hepatologist ,a gastroenterologist

Comments
Post a Comment